Published in Br J Cancer on April 01, 2000
Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer (2005) 1.66
The stem cell factor antibody enhances the chemotherapeutic effect of adriamycin on chemoresistant breast cancer cells. Cancer Cell Int (2012) 1.44
Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell (1990) 5.06
Transmembrane form of the kit ligand growth factor is determined by alternative splicing and is missing in the Sld mutant. Cell (1991) 3.60
Enhanced expression of a glyceraldehyde-3-phosphate dehydrogenase gene in human lung cancers. Cancer Res (1987) 2.65
IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J Immunol (1993) 2.44
Differential expression and processing of two cell associated forms of the kit-ligand: KL-1 and KL-2. Mol Biol Cell (1992) 2.01
Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res (1985) 1.85
Soluble and cell-bound forms of steel factor activity play distinct roles in melanocyte precursor dispersal and survival on the lateral neural crest migration pathway. Development (1995) 1.64
C3a and C5a stimulate chemotaxis of human mast cells. Blood (1997) 1.55
Altered metabolism of mast-cell growth factor (c-kit ligand) in cutaneous mastocytosis. N Engl J Med (1993) 1.52
Chymase cleavage of stem cell factor yields a bioactive, soluble product. Proc Natl Acad Sci U S A (1997) 1.39
Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol (1993) 1.37
Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor. Int J Cancer (1992) 1.34
Establishment and characterization of a human melanoma cell line (MV3) which is highly metastatic in nude mice. Int J Cancer (1991) 1.28
Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J Exp Med (1996) 1.27
Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential. Oncogene (1996) 1.27
Human melanoma: development and progression. Cancer Metastasis Rev (1990) 1.24
A cloned, immortal line of murine melanoblasts inducible to differentiate to melanocytes. Development (1995) 1.15
Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors. Cancer Res (1994) 1.12
Nonhematopoietic tumor cell lines express stem cell factor and display c-kit receptors. Blood (1992) 1.11
Metastatic potential of human melanoma cells in nude mice--characterisation of phenotype, cytokine secretion and tumour-associated antigens. Br J Cancer (1996) 1.09
Role of the KIT protooncogene in normal and malignant human hematopoiesis. Proc Natl Acad Sci U S A (1992) 1.09
Expression of stem cell factor and c-kit in human neuroblastoma. The Children's Cancer Group. Blood (1994) 1.08
Tumour progression and metastatic behaviour in vivo correlates with integrin expression on melanocytic tumours. J Pathol (1993) 1.08
Identification and mutation of primary and secondary proteolytic cleavage sites in murine stem cell factor cDNA yields biologically active, cell-associated protein. J Biol Chem (1994) 1.07
Juxtacrine cell signaling molecules. Curr Opin Cell Biol (1993) 1.02
Phenotypic evaluation of cultured human mast and basophilic cells and of normal human skin mast cells. Arch Dermatol Res (1994) 1.02
Stem cell factor, a novel cutaneous growth factor for mast cells and melanocytes. Arch Dermatol Res (1994) 0.98
Release of stem cell factor from a human keratinocyte line, HaCaT, is increased in differentiating versus proliferating cells. J Invest Dermatol (1996) 0.92
Effect of the Steel gene product on melanogenesis in avian neural crest cell cultures. Differentiation (1994) 0.90
Human recombinant stem-cell factor induces melanocytic hyperplasia in susceptible patients. J Am Acad Dermatol (1995) 0.89
Characterization of gene regulatory elements for selective gene expression in human melanoma cells. Biochem Biophys Res Commun (1995) 0.88
Expression of stem cell factor in cutaneous mastocytosis. Br J Dermatol (1995) 0.85
Human mast cells produce and differentially express both soluble and membrane-bound stem cell factor. Scand J Immunol (1999) 0.83
Coordinated mRNA expression of c-Kit with tyrosinase and TRP-1 in melanin pigmentation of normal and malignant human melanocytes and transient activation of tyrosinase by Kit/SCF-R. Melanoma Res (1995) 0.83
Recombinant human stem cell factor does exert minor stimulation of growth in small cell lung cancer and melanoma cell lines. Eur J Cancer (1995) 0.83
Expression of growth factor receptors on human melanoma cells: comparison of modulating effects of interferons and retinoids. Exp Dermatol (1993) 0.82
Immunohistochemical localisation of stem cell factor (SCF) with comparison of its receptor c-Kit proto-oncogene product (c-KIT) in melanocytic tumours. Virchows Arch (1995) 0.82
Mast cells in melanocytic tumours. Arch Dermatol Res (1995) 0.82
Autocrine regulation of neural crest cell development by steel factor. Dev Biol (1997) 0.81
Stem cell factor regulates human melanocyte-matrix interactions. Pigment Cell Res (1994) 0.80
Expression of the c-kit receptor in hypomelanosis: a comparative study between piebaldism, naevus depigmentosus and vitiligo. Br J Dermatol (1995) 0.78
Human peripheral blood granulocytes and myeloid leukemic cell lines express both transcripts encoding for stem cell factor. Stem Cells (1994) 0.77
[Stem cell factor/c-kit interaction in primordial germ cell, melanoblast and hematopoietic progenitors]. Gan To Kagaku Ryoho (1992) 0.76
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70
Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med (1998) 7.48
Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: implications for the biological significance of VEGF206. Mol Biol Cell (1998) 2.24
Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer (2005) 1.66
Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. Ann Oncol (2014) 1.63
C3a and C5a stimulate chemotaxis of human mast cells. Blood (1997) 1.55
EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy (2006) 1.55
Melanocytes as "sensory" and regulatory cells in the epidermis. J Theor Biol (1993) 1.55
Mast cells. Int J Dermatol (1995) 1.52
Is a single oral dose of ivermectin sufficient in crusted scabies? Int J Dermatol (2001) 1.44
Human mast cells produce IL-8. J Immunol (1993) 1.44
Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanoma. Onkologie (2004) 1.43
Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma. J Pathol (1999) 1.40
[Urticaria pigmentosa and mastocytosis]. Dtsch Med Wochenschr (1998) 1.38
TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. Br J Cancer (2013) 1.38
Increased expression of epidermal fatty acid binding protein, cofilin, and 14-3-3-sigma (stratifin) detected by two-dimensional gel electrophoresis, mass spectrometry and microsequencing of drug-resistant human adenocarcinoma of the pancreas. Electrophoresis (1999) 1.30
Reduced serum 25-hydroxyvitamin D levels in stage IV melanoma patients. Anticancer Res (2009) 1.29
EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy (2006) 1.28
Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J Immunother (2000) 1.27
Serological detection of cutaneous T-cell lymphoma-associated antigens. Proc Natl Acad Sci U S A (2001) 1.24
The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice. Br J Cancer (1999) 1.22
Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol (1997) 1.20
Deficient IL-12p70 secretion by dendritic cells based on IL12B promoter genotype. Genes Immun (2004) 1.18
Biomarkers in melanoma. Ann Oncol (2009) 1.17
Drug-resistance in human melanoma. Int J Cancer (2001) 1.15
Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using two-dimensional electrophoresis. Electrophoresis (2000) 1.14
Mast cells and their mediators in cutaneous wound healing--active participants or innocent bystanders? Exp Dermatol (1999) 1.13
Primary staging and follow-up in melanoma patients--monocenter evaluation of methods, costs and patient survival. Br J Cancer (2002) 1.11
Acute urticaria: clinical aspects and therapeutic responsiveness. Acta Derm Venereol (1996) 1.10
A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer (2011) 1.10
Metastatic potential of human melanoma cells in nude mice--characterisation of phenotype, cytokine secretion and tumour-associated antigens. Br J Cancer (1996) 1.09
Small molecules and targeted therapies in distant metastatic disease. Ann Oncol (2009) 1.08
Miliaria crystallina in an intensive care setting. Clin Exp Dermatol (2004) 1.08
Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. J Invest Dermatol (1998) 1.06
Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT. Int J Cancer (2001) 1.05
Membrane transport proteins associated with drug resistance expressed in human melanoma. Am J Pathol (1995) 1.04
Human dendritic cells infected by Listeria monocytogenes: induction of maturation, requirements for phagolysosomal escape and antigen presentation capacity. Eur J Immunol (2000) 1.04
Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. Br J Cancer (2002) 1.03
Dose-dependent severe cutaneous reactions to imatinib. Br J Cancer (2003) 1.03
DFNA5 (ICERE-1) contributes to acquired etoposide resistance in melanoma cells. FEBS Lett (2001) 1.03
Keratin 17 gene expression during the murine hair cycle. J Invest Dermatol (1997) 1.03
Topical calcitriol enhances normal hair regrowth but does not prevent chemotherapy-induced alopecia in mice. Cancer Res (1996) 1.02
Reversible binding of 5- and 8-methoxypsoralen to human serum proteins (albumin) and to epidermis in vitro. Br J Dermatol (1979) 1.02
Phenotypic evaluation of cultured human mast and basophilic cells and of normal human skin mast cells. Arch Dermatol Res (1994) 1.02
Upregulation of TNF-alpha and IL-3 expression in lesional and uninvolved skin in different types of urticaria. J Allergy Clin Immunol (1999) 1.01
Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1- and H2-receptor antagonists. Exp Dermatol (2000) 0.97
Mast cells and vasculature in atopic dermatitis--potential stimulus of neoangiogenesis. Allergy (2005) 0.97
Detection of native human complement components C3 and C5 and their primary activation peptides C3a and C5a (anaphylatoxic peptides) by ELISAs with monoclonal antibodies. J Immunol Methods (1988) 0.97
Cutaneous large B-cell lymphoma of the leg masquerading as a chronic venous ulcer. Br J Dermatol (2002) 0.97
Impact of vaccinations and infectious diseases on the risk of melanoma--evaluation of an EORTC case-control study. Eur J Cancer (2003) 0.97
Identification of differentially expressed genes in human melanoma cells with acquired resistance to various antineoplastic drugs. Int J Cancer (2000) 0.96
Expression and functional activity of the IL-8 receptor type CXCR1 and CXCR2 on human mast cells. J Immunol (1998) 0.96
The polymerase chain reaction. Method and applications in dermatopathology. Am J Dermatopathol (1993) 0.96
Substance use and sexual risk behaviour among HIV-positive men who have sex with men in specialized out-patient clinics. HIV Med (2012) 0.96
MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome. Br J Cancer (2010) 0.96
Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions. J Clin Pathol (2001) 0.96
Identification of chemotactic lipoxygenase products of arachidonate metabolism in psoriatic skin. J Invest Dermatol (1984) 0.95
Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study. Gene Ther (1998) 0.95
Molecular regulation of human IgE synthesis. J Mol Med (Berl) (1997) 0.95
Human skin mast cells rapidly release preformed and newly generated TNF-alpha and IL-8 following stimulation with anti-IgE and other secretagogues. Exp Dermatol (2001) 0.94
Mastocytosis: recent advances in defining the disease. Br J Dermatol (2001) 0.94
Differential expression of angiotensin receptors in human cutaneous wound healing. Br J Dermatol (2005) 0.94
Biological and chemical characterization of eosinophil chemotactic factors from human leukocytes. Agents Actions Suppl (1983) 0.93
Quantitative detection of soluble adhesion molecules in sera of melanoma patients correlates with clinical stage. Dermatology (1996) 0.93
Infections and melanoma risk: results of a multicentre EORTC case-control study. European Organization for Research and Treatment of Cancer. Melanoma Res (1999) 0.93
Identification of a new HLA-A(*)0201-restricted T-cell epitope from the tyrosinase-related protein 2 (TRP2) melanoma antigen. Int J Cancer (2000) 0.93
Chemotactic leukotrienes in psoriasis. Lancet (1982) 0.92
Polidocanol foam sclerotherapy is a new and effective treatment for post-operative lymphorrhea and lymphocele. J Eur Acad Dermatol Venereol (2010) 0.92
Release of stem cell factor from a human keratinocyte line, HaCaT, is increased in differentiating versus proliferating cells. J Invest Dermatol (1996) 0.92
Evaluation of systemic provocation tests in patients with suspected allergic and pseudoallergic drug reactions. Acta Derm Venereol (1999) 0.91
Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance. Br J Cancer (2000) 0.91
Novel unconventional therapeutic approaches to atopic eczema. Dermatology (2000) 0.91
SEREX identification of new tumour-associated antigens in cutaneous T-cell lymphoma. Br J Dermatol (2004) 0.91
Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). Ann Oncol (2008) 0.91
Production of interleukin-6 by human mast cells and basophilic cells. J Invest Dermatol (1996) 0.91
Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival. An European Organization for Research and Treatment of Cancer cohort study on 542 patients. Eur J Cancer (2005) 0.91
Erythema elevatum diutinum--evidence for disease-dependent leucocyte alterations and response to dapsone. Br J Dermatol (2000) 0.90
Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study. Br J Cancer (1998) 0.90
Functional HLA-DM on the surface of B cells and immature dendritic cells. EMBO J (2000) 0.90
Retinoic acid inhibits CD40 + interleukin-4-mediated IgE production in vitro. Blood (1998) 0.90
Microscopic morphology of different types of urticaria. Arch Dermatol (1998) 0.90
Foreign-body granuloma and IgE-pseudolymphoma after multiple bee stings. Br J Dermatol (1994) 0.89
Definition, classification, and routine diagnosis of urticaria: a consensus report. J Investig Dermatol Symp Proc (2001) 0.89
Allopurinol: a therapeutic alternative for disseminated cutaneous sarcoidosis. Br J Dermatol (1996) 0.89
Comparative cytokine gene expression: regulation and release by human mast cells. Immunology (1998) 0.89
Double-blind crossover study of high-dose cetirizine in cholinergic urticaria. Dermatology (1996) 0.89
Urticarial vasculitis syndrome effectively treated with dapsone and pentoxifylline. Acta Derm Venereol (1995) 0.89
Patterns of constitutive and IFN-gamma inducible expression of HLA class II molecules in human melanoma cell lines. Immunogenetics (2006) 0.88